Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

GeNeuro

DB:GEM
Snowflake Description

High growth potential with imperfect balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
GEM
DB
€62M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. The last earnings update was 1 day ago. More info.


Add to Portfolio Compare Print
  • GeNeuro has significant price volatility in the past 3 months.
GEM Share Price and Events
7 Day Returns
-4.6%
DB:GEM
5.2%
DE Biotechs
4.3%
DE Market
1 Year Returns
-30.1%
DB:GEM
-7.4%
DE Biotechs
-14.2%
DE Market
GEM Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
GeNeuro (GEM) -4.6% -0.7% -15.4% -30.1% -68.4% -
DE Biotechs 5.2% -3.3% -20.3% -7.4% 19.5% -9.4%
DE Market 4.3% -9% -21.6% -14.2% -19.6% -25.6%
1 Year Return vs Industry and Market
  • GEM underperformed the Biotechs industry which returned -7.4% over the past year.
  • GEM underperformed the Market in Germany which returned -14.2% over the past year.
Price Volatility
GEM
Industry
5yr Volatility vs Market

Value

 Is GeNeuro undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for GeNeuro. This is due to cash flow or dividend data being unavailable. The share price is €2.92.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for GeNeuro's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are GeNeuro's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:GEM PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in EUR €-0.65
ENXTPA:GNRO Share Price ** ENXTPA (2020-04-08) in EUR €3
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 43.07x
Germany Market PE Ratio Median Figure of 402 Publicly-Listed Companies 17.07x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of GeNeuro.

DB:GEM PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ENXTPA:GNRO Share Price ÷ EPS (both in EUR)

= 3 ÷ -0.65

-4.62x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • GeNeuro is loss making, we can't compare its value to the Europe Biotechs industry average.
  • GeNeuro is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does GeNeuro's expected growth come at a high price?
Raw Data
DB:GEM PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -4.62x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
58.7%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.71x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.24x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for GeNeuro, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on GeNeuro's assets?
Raw Data
DB:GEM PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in EUR €0.07
ENXTPA:GNRO Share Price * ENXTPA (2020-04-08) in EUR €3
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.37x
Germany Market PB Ratio Median Figure of 573 Publicly-Listed Companies 1.47x
DB:GEM PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ENXTPA:GNRO Share Price ÷ Book Value per Share (both in EUR)

= 3 ÷ 0.07

43.68x

* Primary Listing of GeNeuro.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • GeNeuro is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess GeNeuro's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. GeNeuro has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is GeNeuro expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
58.7%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is GeNeuro expected to grow at an attractive rate?
  • GeNeuro's earnings growth is expected to exceed the low risk savings rate of -0.4%.
Growth vs Market Checks
  • GeNeuro's earnings growth is expected to exceed the Germany market average.
  • GeNeuro's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:GEM Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:GEM Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts 58.7%
DB:GEM Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 147.3%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 38.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.2%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:GEM Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:GEM Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-12-31 44 3 1
2020-12-31 0 -14 -14 2
2020-04-08
DB:GEM Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2019-12-31 -9
2019-09-30 0 -10
2019-06-30 0 -15 -10
2019-03-31 4 -16 -9
2018-12-31 7 -18 -8
2018-09-30 13 -12 -4
2018-06-30 19 -6 0
2018-03-31 17 -7 -3
2017-12-31 15 -8 -6
2017-09-30 10 -13 -11
2017-06-30 6 -19 -16
2017-03-31 6 -16 -15

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • GeNeuro's earnings are expected to grow significantly at over 20% yearly.
  • GeNeuro's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:GEM Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from GeNeuro Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:GEM Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-12-31
2020-12-31 -0.70 -0.70 -0.70 1.00
2020-04-08
DB:GEM Past Financials Data
Date (Data in EUR Millions) EPS *
2019-12-31 -0.65
2019-09-30 -0.68
2019-06-30 -0.72
2019-03-31 -0.64
2018-12-31 -0.57
2018-09-30 -0.29
2018-06-30 -0.01
2018-03-31 -0.21
2017-12-31 -0.40
2017-09-30 -0.75
2017-06-30 -1.11
2017-03-31 -1.06

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if GeNeuro will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess GeNeuro's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
GeNeuro has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has GeNeuro performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare GeNeuro's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • GeNeuro does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare GeNeuro's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare GeNeuro's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
GeNeuro's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from GeNeuro Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:GEM Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 -9.46 3.74 5.26
2019-09-30 0.06 -9.96 4.16 5.41
2019-06-30 0.12 -10.46 4.42 5.71
2019-03-31 3.79 -9.39 4.67 8.19
2018-12-31 7.46 -8.33 4.92 10.67
2018-09-30 13.24 -4.26 4.79 12.63
2018-06-30 19.02 -0.19 4.52 14.74
2018-03-31 16.98 -3.01 4.69 15.30
2017-12-31 14.95 -5.84 4.85 15.85
2017-09-30 10.36 -11.01 4.01 16.34
2017-06-30 5.76 -16.18 3.18 16.83
2017-03-31 5.84 -15.14 3.50 15.54
2016-12-31 5.92 -14.10 3.83 14.25
2016-09-30 5.68 -11.41 4.25 11.81
2016-06-30 5.45 -8.71 4.68 9.38
2016-03-31 3.99 -6.60 3.32 7.12
2015-12-31 2.54 -4.49 1.97 4.87
2015-09-30 5.18 -1.26 1.81 4.18
2015-06-30 7.81 1.96 1.65 3.49
2015-03-31 7.56 1.87 1.56 3.54
2014-12-31 7.31 1.78 1.48 3.60
2013-12-31 0.02 -3.50 0.75 2.61

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if GeNeuro has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if GeNeuro has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if GeNeuro improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess GeNeuro's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
GeNeuro has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is GeNeuro's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up GeNeuro's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • GeNeuro is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • GeNeuro's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of GeNeuro's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 1.5x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from GeNeuro Company Filings, last reported 3 months ago.

DB:GEM Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31
2019-09-30
2019-06-30 1.00 7.69 9.99
2019-03-31 1.00 7.69 9.99
2018-12-31 5.55 0.19 9.00
2018-09-30 5.55 0.19 9.00
2018-06-30 11.09 0.18 17.32
2018-03-31 11.09 0.18 17.32
2017-12-31 13.06 0.22 26.60
2017-09-30 13.06 0.22 26.60
2017-06-30 10.68 0.22 23.10
2017-03-31 10.68 0.22 23.10
2016-12-31 18.67 0.18 34.49
2016-09-30 18.67 0.18 34.49
2016-06-30 25.65 0.18 42.41
2016-03-31 25.65 0.18 42.41
2015-12-31 1.69 0.18 19.56
2015-09-30 1.69 0.18 19.56
2015-06-30 4.55 0.17 7.02
2015-03-31 4.55 0.17 7.02
2014-12-31 6.24 0.17 7.86
2013-12-31 2.71 0.49 3.18
  • GeNeuro's level of debt (767.3%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (7.4% vs 767.3% today).
  • Operating cash flow is negative therefore debt is not well covered.
  • Unable to confirm if the interest payments on GeNeuro's debt are well covered by earnings due to lack of past financial data.
X
Financial health checks
We assess GeNeuro's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. GeNeuro has a total score of 2/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is GeNeuro's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from GeNeuro dividends. Estimated to be 0% next year.
If you bought €2,000 of GeNeuro shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate GeNeuro's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate GeNeuro's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:GEM Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 314 Stocks 3.6%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.6%
Germany Top 25% Dividend Yield 75th Percentile 4.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:GEM Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2021-12-31
2020-12-31 0.00 1.00
2020-04-08

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as GeNeuro has not reported any payouts.
  • Unable to verify if GeNeuro's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of GeNeuro's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as GeNeuro has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of GeNeuro's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess GeNeuro's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can GeNeuro afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. GeNeuro has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of GeNeuro's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Jesus Martin-Garcia
COMPENSATION €694,000
AGE 57
TENURE AS CEO 4.3 years
CEO Bio

Mr. Jesús Martin-Garcia is the Founding Partner, General Partner, and Director of Eclosion SA. He serves at GeNeuro SA as the Chairman of the Board since February 06, 2006 and Chief Executive Officer since January 01, 2016. Since 2004, he has been contributing to the companies created by Eclosion, serving as CEO in the early development stages, and later as Executive Chairman to help drive financial rounds and partnerships with pharma companies. He served as the Chief Executive Officer of GeNeuro SA. Mr. Martin-Garcia co-founded Le Shop SA in 1977. Since 1996, he has been active investing seed capital, supporting a number of start-ups in the Geneva region such as Silverwire. He started his career at the World Economic Foundation, and later at McKinsey & Co. focusing on Pharma and Food industries. He co-founded LeShop. He started a consulting career at McKinsey & Co. focusing on pharma and food industries. In 1993, Mr. Martin-Garcia served as the Founding Partner of Value Management Group. He served as Strategic Advisor to Eurpean incumbent Telcos for over a decade. Mr. Martin-Garcia serves as the Chairman of ArisGen SA. He serves as a Director of Eclosion SA and He has been a Director of GenKyoTex SA since February 28, 2017. He sits on the Board of the Harvard Business School Health Alumni Association. He obtained BS in Business Administration and a BA in law from the University of Geneva. He has entrepreneurial experience in managing successful start-ups. Mr. Martin-Garcia has a MS in Economics and a Master in Law from University of Geneva, and an MBA from Harvard Business School.

CEO Compensation
  • Jesus's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Jesus's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the GeNeuro management team in years:

4.3
Average Tenure
55.5
Average Age
  • The tenure for the GeNeuro management team is about average.
Management Team

Jesus Martin-Garcia

TITLE
Chairman & CEO
COMPENSATION
€694K
AGE
57
TENURE
4.3 yrs

Miguel Payró

TITLE
Chief Financial Officer
AGE
54
TENURE
4.3 yrs

François Curtin

TITLE
COO & Interim Chief Medical Officer
AGE
54
TENURE
11.3 yrs

Hervé Perron

TITLE
Chief Scientific Officer
AGE
60

Thomas Rückle

TITLE
Senior VP & Head of Pre-Clinical Development
TENURE
3.3 yrs
Board of Directors Tenure

Average tenure and age of the GeNeuro board of directors in years:

4.9
Average Tenure
62
Average Age
  • The tenure for the GeNeuro board of directors is about average.
Board of Directors

Jesus Martin-Garcia

TITLE
Chairman & CEO
COMPENSATION
€694K
AGE
57
TENURE
14.2 yrs

Christophe Guichard

TITLE
Director
AGE
49
TENURE
4.4 yrs

Jean-Jacques Laborde

TITLE
Independent Director
AGE
73
TENURE
6.2 yrs

Michel Dubois

TITLE
Independent Director
COMPENSATION
€22K
AGE
76
TENURE
11.8 yrs

Gordon Francis

TITLE
Independent Director
COMPENSATION
€31K
AGE
69
TENURE
5.1 yrs

Giacomo Di Nepi

TITLE
Independent Director
COMPENSATION
€23K
AGE
66
TENURE
4.8 yrs

Eric Falcand

TITLE
Independent Director
AGE
57
TENURE
4.4 yrs

Marc Bonneville

TITLE
Independent Director
AGE
58
TENURE
4.4 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess GeNeuro's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. GeNeuro has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. Its lead therapeutic candidate is temelimab, a monoclonal antibody, which has completed Phase IIb clinical trial for the treatment of multiple sclerosis; and is in Phase IIa to treat type 1 diabetes, as well as is in Phase I for the treatment of chronic inflammatory demyelinating polyneuropathy. The company has cooperative research and development agreements with The National Institute of Neurological Disorders and Stroke to develop novel therapeutic antibodies for the treatment of amyotrophic lateral sclerosis; and Academic labs to develop inflammatory psychosis. GeNeuro SA was founded in 2006 and is headquartered in Plan-les-Ouates, Switzerland.

Details
Name: GeNeuro SA
GEM
Exchange: DB
Founded: 2006
€61,533,249
20,511,083
Website: http://www.geneuro.ch
Address: GeNeuro SA
3 chemin du Pré-Fleuri,
Plan-les-Ouates,
Geneva, 1228,
Switzerland
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ENXTPA GNRO Class C Common Shares Euronext Paris FR EUR 15. Apr 2016
OTCPK GNRR.F Class C Common Shares Pink Sheets LLC US USD 15. Apr 2016
DB GEM Class C Common Shares Deutsche Boerse AG DE EUR 15. Apr 2016
LSE 0RHK Class C Common Shares London Stock Exchange GB EUR 15. Apr 2016
Number of employees
Current staff
Staff numbers
24
GeNeuro employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/08 22:45
End of day share price update: 2020/04/08 00:00
Last estimates confirmation: 2020/04/07
Last earnings filing: 2020/04/07
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.